Matrixyl.
Matrixyl is the trade name (Sederma/Croda) for palmitoyl pentapeptide-4, also written pal-KTTKS or palmitoyl-Lys-Thr-Thr-Lys-Ser.
Matrixyl is the trade name (Sederma/Croda) for palmitoyl pentapeptide-4, also written pal-KTTKS or palmitoyl-Lys-Thr-Thr-Lys-Ser. Matrixyl is cosmetic / topical, and PepCue grades its published evidence D tier (37/100). Also known as palmitoyl pentapeptide. This is a research reference, not medical or dosing advice.
What it is
Matrixyl is the trade name (Sederma/Croda) for palmitoyl pentapeptide-4, also written pal-KTTKS or palmitoyl-Lys-Thr-Thr-Lys-Ser. It is a synthetic cosmetic peptide consisting of a five-amino-acid fragment of type I procollagen (the KTTKS sequence) conjugated to palmitic acid, a fatty-acid tail added to improve lipophilicity and skin penetration. It is sold as a topical anti-aging skincare active, not as a drug or an injectable; the related blend "Matrixyl 3000" pairs a different peptide (palmitoyl tripeptide-1 / pal-GHK) with palmitoyl tetrapeptide-7.
How it works
KTTKS is a sub-fragment of the C-terminal propeptide of type I collagen. Liberation of such procollagen fragments during matrix turnover is thought to act as a feedback signal that up-regulates new extracellular matrix synthesis, so the peptide is described as a "matrikine" or signal peptide rather than a hormone or growth factor. In cultured human dermal fibroblasts, KTTKS and pal-KTTKS have been reported to stimulate production of type I and III collagen, fibronectin, and glycosaminoglycans. The palmitoyl tail is non-functional pharmacologically; its role is to make the otherwise hydrophilic peptide lipophilic enough to cross the stratum corneum. The peptide does not relax muscle (it is not a "Botox-like" neuromodulator, unlike acetyl hexapeptide-8/Argireline).
Mechanism pathways
Signalling that builds, protects, or remodels the structural scaffold around cells.
The extracellular matrix is the scaffold cells live in: collagens for tensile strength, elastin for recoil, fibronectin and laminin for adhesion, and proteoglycans and glycosaminoglycans that hold water and govern how signalling molecules diffuse. It is not inert. It is continuously synthesised and degraded, with matrix metalloproteinases doing the cutting and tissue inhibitors of metalloproteinases restraining them. Ageing, ultraviolet exposure, and chronic inflammation shift this balance toward net loss, which is the structural basis of skin ageing and of several degenerative conditions. One route into this system is the matrikine concept. When collagen is degraded, specific short fragments are liberated, and these fragments appear to act as feedback signals telling fibroblasts to make more matrix. A pentapeptide from the carboxy-terminal propeptide of type I collagen is the best-known example, and in cultured dermal fibroblasts it has been reported to stimulate production of type I and type III collagen, fibronectin, and glycosaminoglycans. Because the peptide itself is hydrophilic, a fatty palmitoyl tail is attached purely to make it lipophilic enough to cross the stratum corneum. That tail has no pharmacological role of its own, a detail frequently misrepresented. A second route works through copper coordination, supplying a cofactor for the enzymes that cross-link collagen and elastin while also modulating matrix metalloproteinase activity, which affects both the building and the breaking side of remodelling. A third acts protectively rather than synthetically. A semi-synthetic sulfated polysaccharide with a heparin-like structure behaves as an exogenous glycosaminoglycan, proposed to adhere to and replenish the protective glycosaminoglycan layer lining the bladder urothelium so that irritating urinary solutes reach underlying nerves less readily. Its structure also gives it mild anticoagulant activity and the ability to bind growth factors and inhibit heparanase, which is the basis for separate interest in joint and inflammatory contexts. Honesty about evidence: the matrikine peptides are cosmetic ingredients, not drugs, and cosmetic ingredients need not demonstrate clinical efficacy. Fibroblast responses in culture are well documented; controlled human trials showing meaningful structural change in skin are far more limited. The bladder agent is an approved prescription medicine, but its own label states that the precise mechanism is unknown, and long-term use has been associated with a distinctive retinal disorder that requires ophthalmological monitoring.
The evidence
Human evidence comes from cosmetic split-face/vehicle-controlled topical trials, not drug-grade efficacy programs. The most cited is Robinson et al. (Int J Cosmet Sci, 2005), a 12-week double-blind, vehicle-controlled, split-face study in 93 women (ages 35-55) where a moisturizer with 3 ppm pal-KTTKS gave statistically significant reductions in fine lines/wrinkles versus the same vehicle by quantitative image analysis, expert grading, and self-assessment, and was well tolerated. A daily-moisturizer study published in JAAD (2004) similarly reported improvement in the appearance of aging skin. A 2023 double-blind RCT in the Journal of Clinical and Aesthetic Dermatology compared palmitoyl pentapeptide-4 cream with acetyl hexapeptide-3 for crow's feet. Importantly, headline figures often quoted in marketing (e.g. "stimulates collagen by ~350%" or large fibronectin increases) derive from in-vitro fibroblast assays, not human skin, and effect sizes in human trials are modest; independent head-to-head data versus retinoids remain limited.
The evidence, in brief
A topical cosmetic signal peptide (palmitoyl pentapeptide / pal-KTTKS) intended to stimulate dermal matrix synthesis. Supporting data are small split-face cosmetic trials showing modest fine-line improvement with good tolerability: cosmetic and incremental, not clinically dramatic.
- Topical palmitoyl pentapeptide provides improvement in photoaged human facial skinInt J Cosmet Sci, 2005 (PMID 18492182)
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #039
Mostly preclinical or mechanistic; little human data.
Some early human evidence exists but isn't definitive.
Claim receipts
Popular claims about Matrixyl, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
A twelve-week double-blind, vehicle-controlled split-face study plus supporting cosmetic trials found measurable improvement in line appearance.
The large percentage figures used in marketing come from fibroblast assays in culture; human effects are real but modest.
Independent head-to-head comparisons against retinoids are limited, so the equivalence claim is not established.
Topical trials report low irritation and sensitization rates, but comparative tolerability against retinoids has not been formally tested.
Safety profile
In the published topical trials pal-KTTKS was well tolerated, with low rates of irritation, erythema, or sensitization and a generally favorable cosmetic safety profile, one reason it is often positioned as a gentler alternative to retinoids. The Cosmetic Ingredient Review and EU cosmetic frameworks treat palmitoyl oligopeptides as safe for topical use at the low concentrations used in finished products. That said, safety data are specific to topical, leave-on cosmetic use at trace concentrations; there is no established safety profile for injected, oral, or high-concentration use, and such routes are not a recognized use of this ingredient. As with any topical, individual allergic or irritant contact reactions are possible, and pregnancy/long-term systemic data are essentially absent because systemic exposure from topical use is expected to be negligible.
Compound notes
- Matrixyl is a palmitoyl peptide (e.g. palmitoyl pentapeptide) used as a topical cosmetic ingredient.
- It is studied for stimulating collagen/matrix proteins in skin, a cosmetic, topical context.
- A cosmetic ingredient, not a drug; topical use.
- Systemic anti-aging benefit is not the claim: effects are topical and modest.
Regulatory status
Matrixyl/palmitoyl pentapeptide-4 is regulated as a cosmetic ingredient, not an FDA-approved drug; it makes appearance ("cosmetic") claims rather than treatment claims and has not undergone FDA drug approval. It is widely used in over-the-counter skincare in the US, EU, and elsewhere, and is not a controlled substance or a WADA-prohibited compound.
Used topically as a cosmetic ingredient, not an approved drug.
By the numbers
- 01Chemical identity: palmitoyl-KTTKS (palmitoyl pentapeptide-4), a procollagen I fragment with a palmitic-acid tail for skin penetration
- 02It is a topical cosmetic 'signal/matrikine' peptide, not a muscle-relaxing peptide and not a growth factor
- 03Matrixyl 3000 is a different marketed blend (palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7), not the same molecule as original Matrixyl
- 04Pivotal human data: Robinson 2005, a 12-week vehicle-controlled split-face trial in 93 women using only 3 ppm pal-KTTKS
- 05Large collagen/fibronectin stimulation percentages come from cell-culture assays, not human skin
- 06Regulated as a cosmetic ingredient; no FDA drug approval and no recognized injectable/oral use
Matrixyl: research formats
Choose the format you are researching to see route-specific notes.
Palmitoyl pentapeptide; designed for dermal application, not systemic use.
Matrixyl (palmitoyl pentapeptide-4) is a lipophilic peptide designed for topical use: the palmitoyl fatty acid chain anchors it in the lipid bilayer and aids dermal penetration. It is sold as a finished cosmetic ingredient, not as a lyophilized injectable. Applied topically in serums or creams.
The published human data for matrixyl is from topical application studies. There is no evidence base for systemic or injectable use.
Sources
Every factual claim above resolves to a real, published source.
- Topical palmitoyl pentapeptide provides improvement in photoaged human facial skinInternational Journal of Cosmetic Science, 2005, PMID 18492182
- Use of a facial moisturizer containing palmitoyl pentapeptide improves the appearance of aging skinJournal of the American Academy of Dermatology, 2004
- Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's FeetJournal of Clinical and Aesthetic Dermatology, 2023, PMID 36909866
- Liquid chromatography-tandem mass spectrometry to determine the stability of collagen pentapeptide (KTTKS) in rat skinJournal of Chromatography B, 2012, PMID 22921149
Cite this page
PepCue. “Matrixyl: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/matrixyl.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.